免疫检查点抑制剂治疗肿瘤的作用机制及其免疫相关不良反应的研究进展

Review on immune checkpoint inhibition in cancer treatment and its immune-related adverse events

免疫检查点抑制剂(immune checkpoint inhibitors, ICIs)是一种能激活免疫系统的单克隆抗体,旨在增强抗肿瘤免疫。尽管大量研究已证明其临床疗效,ICIs应用导致免疫相关不良事件(immune related adverse events, irAEs)包括常见的炎性关节炎、风湿性多肌痛和肌炎等逐渐引起临床关注。在此,我们针对ICIs治疗肿瘤的作用机制及所致免疫相关不良反应综述近期的研究进展。

Immune checkpoint inhibitors(ICIs) are monoclonal antibodies that can activate immune system with anti-tumor immunity. Although the clinical efficacies of ICIs have been extensively demonstrated in cancer immunotherapy, there is increasing attention to ICI-mediated immune-related adverse events including inflammatory arthritis, polymyalgia rheumatic and myositis. Here, we review recent advance in mechanistic studies on immune checkpoint inhibition therapy for cancers and rheumatic immune-related adverse events.